Doha Drug Store

dohadrugstore.com

Doha Drug Store, one of Qatar’s premier Trading Companies, represents a list of 46 exclusive agencies in the Consumer goods and Pharmaceutical (Generic & Research) Industries. Founded in 1960 by Nasser Bin Khalid & Ali Bin Ali, as a Pharmaceutical Trading Company, the firm has since grown into one of Qatar’s major fast moving consumer goods (FMCG) suppliers, which fully operates its own warehousing, distribution and retail outlets, bringing timely products and services to the customer. Doha Drug Store has a proud heritage of servicing Qatar’s consumer market. Its products are sourced from worldwide locations, which stretch across four continents. Having formed partnering relationships with well-established firms in their respective fields of manufacturing and supply, Doha Drug Store is committed to delivering quality to its valued customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

MEDISON PHARMA ANNOUNCES AGREEMENT WITH REGENERON PHARMACEUTICALS TO COMMERCIALIZE LIBTAYO (CEMIPLIMAB) IN MULTIPLE COUNTRIES

PR Newswire | January 08, 2024

news image

Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo (cemiplimab), a fully human...

Read More

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

news image

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More

PHARMACY MARKET, PHARMA TECH

KINDEVA DRUG DELIVERY, CHIESI GROUP, AND H&T PRESSPART ANNOUNCE STRATEGIC PARTNERSHIP FOR DOSE COUNTER TECHNOLOGY PRODUCTION

Businesswire | July 12, 2023

news image

Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart (a division of the Heitkamp & Thumann Group), a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Comb...

Read More

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

news image

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More
news image

PHARMA TECH

MEDISON PHARMA ANNOUNCES AGREEMENT WITH REGENERON PHARMACEUTICALS TO COMMERCIALIZE LIBTAYO (CEMIPLIMAB) IN MULTIPLE COUNTRIES

PR Newswire | January 08, 2024

Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc., a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo (cemiplimab), a fully human...

Read More
news image

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More
news image

PHARMACY MARKET, PHARMA TECH

KINDEVA DRUG DELIVERY, CHIESI GROUP, AND H&T PRESSPART ANNOUNCE STRATEGIC PARTNERSHIP FOR DOSE COUNTER TECHNOLOGY PRODUCTION

Businesswire | July 12, 2023

Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart (a division of the Heitkamp & Thumann Group), a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Comb...

Read More
news image

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us